North America currently maintains the largest market share, accounting for over 41% of global revenue. This regional dominance stems from robust R&D spending and an established infrastructure for clinical trial services. Logistics and distribution remain the most significant segments, capturing 27.2% of the market as companies pivot toward direct-to-patient delivery models that require precise cold-chain management and real-time shipment monitoring.

Pharmaceutical and biotechnology firms are increasingly moving away from fragmented service models in favor of integrated, end-to-end supply platforms. This shift is fueling strategic consolidation, exemplified by major acquisitions such as UPS’s $1.6 billion purchase of Andlauer Healthcare Group and DHL’s acquisition of CRYOPDP. These investments aim to bolster resilience in global supply chains, particularly for Phase III trials and oncology research, which demand stringent regulatory compliance and specialized handling of advanced therapies.